Latest news
Rocket Pharmaceuticals Reports Positive Safety Update for RP-A501 Under Modified Phase 2 Protocol in Danon Disease - BioPharm InternationalBioPharm International · Mon, 03 Aug 2026 17:07:07 GMTRocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease - Business WireBusiness Wire · Mon, 03 Aug 2026 11:00:00 GMT